Iovance Biotherapeutics, Inc. IOVA

IOVA Company Overview

Iovance Biotherapeutics, Inc. is a U.S.-based biotechnology company focused on developing and commercializing tumor infiltrating lymphocyte (TIL) cell therapies for the treatment of solid tumor cancers. The company operates within the biotechnology and immuno-oncology industries, with its core business centered on autologous cell therapies that use a patient’s own immune cells to target and attack cancer. Iovance’s primary commercial and clinical focus is the development of TIL therapies for indications including melanoma, cervical cancer, non-small cell lung cancer, and other solid tumors. Its lead commercial product is lifileucel, marketed as Amtagvi, which became the first FDA-approved TIL therapy for advanced melanoma in the United States in 2024.

The company’s strategic positioning is based on its specialization in TIL therapy manufacturing, clinical development expertise, and proprietary cell therapy processes designed to support scalable production. Iovance was founded in 2007 and evolved from an early-stage biotechnology company into a commercial-stage cell therapy developer through acquisitions, licensing activities, and internal research expansion. Its growth accelerated following advancements in adoptive cell therapy and the expansion of clinical programs targeting difficult-to-treat solid tumors.